A child with severe juvenile dermatomyositis treated with ruxolitinib - Institut Pasteur Access content directly
Journal Articles Brain - A Journal of Neurology Year : 2018

A child with severe juvenile dermatomyositis treated with ruxolitinib

Darragh Duffy
Gillian Rice
  • Function : Author
  • PersonId : 932509

Abstract

Sir, We read with interest the article by Ladislau et al. (2018), highlighting the key role of type I interferon (IFN) in the pathophysiology of the muscle disease observed in dermatomyositis and reporting the short-term efficacy of ruxolitinib in four adult patients. Type I IFNs bind a unique common receptor (IFNAR) and subsequently activate the Janus Kinase 1 (JAK1) and tyrosine kinase 2, which, in turn, leads to the phosphorylation of signal transducer of activator of transcription (STAT) 1 and STAT2 driving the expression of IFN-stimulated genes (ISGs). Here, we describe the use of the JAK1/2 selective inhibitor ruxolitinib in a child with severe vasculopathic refractory juvenile dermatomyositis (JDM). Informed parental consent was obtained for the use of ruxolitinib on a compassionate basis and the associated experimental work, conducted in compliance with the 1975 Declaration of Helsinki [...]

Domains

Immunology

Dates and versions

pasteur-01963025 , version 1 (21-12-2018)

Identifiers

Cite

Florence Aeschlimann, Marie-Louise Frémond, Darragh Duffy, Gillian Rice, Jean-Luc Charuel, et al.. A child with severe juvenile dermatomyositis treated with ruxolitinib. Brain - A Journal of Neurology , 2018, 141 (11), pp.e80. ⟨10.1093/brain/awy255⟩. ⟨pasteur-01963025⟩
90 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More